Evolent

Underrepresentation of minority groups in clinical trials makes it harder to predict how well a new therapy will work in these populations. The representation gap is even wider when it comes to mixed-race individuals. Our chief medical officer emeritus, Andrew Hertler, MD, FACP, recently spoke with BlackDoctor.org about the challenge, the limits of traditional race-based categories, and how genomic profiling could offer a deeper understanding of trial participants — such as how well they metabolize certain drugs. Read the full article: https://lnkd.in/es3wdTrF #clinicaltrials #oncology

At Evolent, we are celebrating Women’s History Month by amplifying women’s voices and experiences. With 67.4% of our workforce identifying as women, we're committed to fostering an inclusive and supportive environment. Hear firsthand from one of our many remarkable women leaders at Evolent about her experience and advice for rising leaders.

On this Employee Appreciation Day, we’re grateful for our team members, who show up every day for patients, our customers, and one another. To recognize and reward our talented and mission-driven workforce, we had a lineup of fun activities including:?? ????♀? A restorative yoga session to help people feel refreshed and energized.?? ?A virtual coffee with senior leaders, who highlighted recent team accomplishments.?? ??????An ergonomics session on setting up our remote workspaces for comfort and productivity??? ?? A discussion on cultivating a gratitude mindset to appreciate the positive in our lives in and out of work.?? Employees also recognized and appreciated each other on our internal social media platform.??? Our people are what make Evolent special, and we appreciate them today and throughout the year.? #EmployeeAppreciationDay

When cancer is caught early, there’s typically a better chance of a cure, while using less invasive, less toxic therapies. Yet one powerful tool to identify high-risk individuals – universal hereditary cancer screenings – goes underused. Evolent’s medical director of genetic testing and oncology imaging, Dr. Sadie Dobrozsi, spoke with DocWire News about who is eligible for these genetic tests, the barriers that keep more people from using them, and how to close the gaps. Watch video: https://lnkd.in/e7U2FCFd #genetictesting #cancer #oncology

Health Care Value Week is here! Take advantage of free opportunities to gain insights on progress toward #valuebasedcare. Events include a virtual panel on Tuesday, February 25, featuring our chief medical officer emeritus, Andrew Hertler, MD, FACP, on value-based approaches in #oncology. ?

Clinical trial participants tend to be healthier, younger and less diverse than the general population. That’s one likely reason that, after new drugs reach the market, outcomes in real-world patients often fall short of those seen in trials. In a recent commentary in AJMC - The American Journal of Managed Care's Evidence Based Oncology, our chief medical officer emeritus, Andrew Hertler, MD, FACP, delves into the problem and how the industry might make trial populations more representative. Read the full article: https://lnkd.in/eXgisAjr #healthequity #oncology #clinicaltrials

Don’t miss the complimentary webinars during Health Care Value Week! Our very own Andrew Hertler, MD, FACP,?will join a panel of industry peers to discuss the integration of oncology into value-based care models. Registration for these events is free. Save your seat today: https://hcvalueweek.org/ #HCValueWeek #valuebasedcare #oncology

Are you ready to make a meaningful impact on patient care in a non-clinical setting? Join our team as a Field Medical Director, Cardiovascular Specialist?and use your expertise in interventional cardiology to help ensure the delivery of high-value, evidence-based care. Enjoy work-life balance while working 100% remote and contributing to better health outcomes in an environment that fosters collaboration and continuous learning. https://lnkd.in/e2xWWRmS #Physicianhiring #Cardio #InterventionalCardiologist #Evolent?

Predicting health risks, streamlining clinician administrative tasks, and leveraging data to drive better health outcomes across communities are just a few ways that AI is transforming patient care and population health – but we’re still in the early stages. In a recent interview with Urban Health Today, Evolent Chief Medical Officer Dr. Von Nguyen explored the current state of healthcare-focused AI, along with the importance of using these technologies in measured and meaningful ways to create equitable improvements in care. Read the Q&A: https://bit.ly/4ha42B7 #Health #Healthcare #ArtificalIntelligence Tamara Thomas

For many oncology drugs approved via the FDA’s accelerated approval pathway, it can take years before it’s clear whether they deliver on their initial promise. How do patients feel about the tradeoff between getting earlier access to these new therapies and having greater certainty of clinical benefit, such as longer survival? This article by our vice president of pharmacy, Terra Wonsettler, Pharm.D., MBA, highlights new data that sheds light on this under-examined question.? https://lnkd.in/evZBqiCd #oncology #healthcare